Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical phase I/II study is to investigate the safety and tolerability
of 177Lu-OPS201 used for the treatment of patients with neuroendocrine tumors (NETs).
Secondary objectives of these study are the assessment of biodistribution, dosimetry and
preliminary efficacy of 177Lu-OPS201.